^
Association details:
| Biomarker: | HER-2 T862A + HER-2 L755S |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Pozenveo (poziotinib) (HER2 inhibitor, HER4 inhibitor, pan-EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
Published date:
09/15/2023
Excerpt:
Herein, we show that secondary acquired HER2T862A and HER2L755S mutations promote resistance to HER2 TKIs...Cells expressing double HER2 mutations exhibited resistance to most HER2 TKIs but retained sensitivity to mobocertinib and poziotinib.
DOI:
10.1158/0008-5472.CAN-22-3617
